# A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection

> **NCT00963885** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 229 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Copegus
- **DRUG:** Pegasys
- **DRUG:** Placebo
- **DRUG:** Placebo
- **DRUG:** RO5190591 (Danoprevir)
- **DRUG:** RO5190591 (Danoprevir)
- **DRUG:** RO5190591 (Danoprevir)
- **DRUG:** RO5190591 (Danoprevir)

## Key facts

- **NCT ID:** NCT00963885
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 229 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00963885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00963885, "A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00963885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*